Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 4/20 | 0.47 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.47 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.47 |
| ▸ | HTR2B | P41595 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1269320 | 1.00 | DRD1 (0.47) | DRD1ABCB11CYP2C19ADRA2ACYP2B6 | |
| Hydrochloric Acid SCHEMBL3077710 | 0.99 | DRD1 (0.46) | DRD1ABCB11CYP2C19ADRA2ACYP2B6 | |
| Hydrochloric Acid SCHEMBL3077705 | 0.99 | DRD1 (0.46) | DRD1ABCB11CYP2C19ADRA2ACYP2B6 | |
| Bromide SCHEMBL2087060 | 0.99 | DRD1 (0.46) | DRD1ABCB11CYP2C19ADRA2ACYP2B6 | |
| Hydrochloric Acid SCHEMBL6615615 | 0.98 | DRD1 (0.45) | DRD1ABCB11CYP2C19ADRA2ACYP2B6 | |
| Sulfuric Acid SCHEMBL951856 | 0.96 | ABCB11 (0.50) | DRD1ABCB11CYP2C19ADRA2ACYP2B6 | |
| Sulfuric Acid SCHEMBL6363639 | 0.96 | ABCB11 (0.50) | DRD1ABCB11CYP2C19ADRA2ACYP2B6 | |
| Sulfuric Acid SCHEMBL6363645 | 0.94 | ABCB11 (0.48) | DRD1ABCB11CYP2C19ADRA2ACYP2B6 | |
| Sulfuric Acid SCHEMBL6375982 | 0.94 | ABCB11 (0.48) | DRD1ABCB11CYP2C19ADRA2ACYP2B6 | |
| SCHEMBL5024497 | 0.88 | ABCB11 (0.42) | DRD1ABCB11CYP2C19ADRA2ACYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4330382-A2 | IN VITRO DRUGS FROM PRODRUGS AND USE THEREOF | Brandenburgische Technische Universität Cottbus-Senftenberg (DE) | 2024-03-06 | — | — | EP | claimed |
| JP-4681545-B2 | — | — | 2011-05-11 | — | — | JP | claimed |
| US-20050113406-A1 | Polymorphs of clopidogrel hydrochloride and their use as antithrombic compounds | EGIS GYOGYSZERGYAR RT. (HU) | 2005-05-26 | — | — | US | claimed |
| WO-2004108665-A2 | A PROCESS FOR PREPARATION OF CLOPIDOGREL | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2004-12-16 | — | — | WO | claimed |
| EP-1474427-A1 | POLYMORPHS OF CLOPIDOGREL HYDROCHLORIDE AND THEIR USE AS ANTITHROMBIC COMPOUNDS | EGIS GYOGYSZERGYAR (HU) | 2004-11-10 | — | — | EP | claimed |
| EP-1438314-A1 | A PROCESS FOR PREPARING ENANTIOMERICALLY PURE ALPHA-PHENYL-APLPHA(6,7-DIHYDRO-4H-THIENO 3,2-C PYRIDIN-5-YL)-ACETIC ACID DERIVATIVES | Merck Generics (UK) Limited (GB) | 2004-07-21 | — | — | EP | claimed |
| WO-2003066637-A1 | POLYMORPHS OF CLOPIDOGREL HYDROCHLORIDE AND THEIR USE AS ANTITHROMBIC COMPOUNDS | EGIS Gyógyszergyár Rt. (HU) | 2003-08-14 | — | — | WO | claimed |
| WO-2003035652-A1 | A PROCESS FOR PREPARING ENANTIOMERICALLY PURE α-PHENYL-α-(6,7-DIHYDRO-4H-THIENO[3,2-C]PYRIDIN-5-YL)-ACETIC ACID DERIVATIVES | MERCK GENERICS [UK] LIMITED (GB) | 2003-05-01 | — | — | WO | claimed |
| US-20240016785-A1 | CLOPIDOGREL FOR USE IN THE TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) | DELTA 4 GMBH (AT) | 2024-01-18 | — | — | US | disclosed |
| EP-1837337-B1 | Novel crystalline polymorphs of clopidogrel | GENERICS UK LTD (GB) | 2016-04-06 | — | — | EP | disclosed |
| EP-1772456-B1 | Novel crystalline polymorphs of clopidogrel | GENERICS UK LTD (GB) | 2014-10-29 | — | — | EP | disclosed |
| WO-2011149110-A1 | NOVEL COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF THROMBOEMBOLISM | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011101865-A2 | STABLE PHARMACEUTICAL COMPOSITIONS OF CLOPIDOGREL FOR PARENTERAL DELIVERY | CADILA HEALTHCARE LIMITED (IN) | 2011-08-25 | — | — | WO | disclosed |
| US-7897613-B2 | Crystalline polymorphs of clopidogrel | GENERICS [UK] LIMITED (GB) | 2011-03-01 | — | — | US | disclosed |
| WO-2004108665-A2 | A PROCESS FOR PREPARATION OF CLOPIDOGREL | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2004-12-16 | — | — | WO | disclosed |
| EP-1474427-A1 | POLYMORPHS OF CLOPIDOGREL HYDROCHLORIDE AND THEIR USE AS ANTITHROMBIC COMPOUNDS | EGIS GYOGYSZERGYAR (HU) | 2004-11-10 | — | — | EP | disclosed |
| WO-2003035652-A9 | A PROCESS FOR PREPARING ENANTIOMERICALLY PURE α-PHENYL-α-(6,7-DIHYDRO-4H-THIENO[3,2-C]PYRIDIN-5-YL)-ACETIC ACID DERIVATIVES | MERCK GENERICS UK LTD (GB) | 2004-04-08 | — | — | WO | disclosed |
| WO-2003066637-A1 | POLYMORPHS OF CLOPIDOGREL HYDROCHLORIDE AND THEIR USE AS ANTITHROMBIC COMPOUNDS | EGIS Gyógyszergyár Rt. (HU) | 2003-08-14 | — | — | WO | disclosed |
| EP-0281459-B1 | Dextrorotatory enantiomer of alpha-(4,5,6,7-tetrahydrothieno[3,2-c]pyrid-5-yl)(2-chlorophenyl)methyl acetate, process for its preparation and pharmaceutical compositions containing it | SANOFI SA (FR) | 1995-04-26 | — | — | EP | disclosed |
| EP-0281459-A1 | Dextrorotatory enantiomer of alpha-(4,5,6,7-tetrahydrothieno[3,2-c]pyrid-5-yl)(2-chlorophenyl)methyl acetate, process for its preparation and pharmaceutical compositions containing it | SANOFI (FR) | 1988-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113406-A1 | Polymorphs of clopidogrel hydrochloride and their use as antithrombic compounds | PLAT, PFKP, P2RY6 | DRD1 3227/4885ABCB11 263/4885CYP2C19 12/4885 |
| US-20240016785-A1 | CLOPIDOGREL FOR USE IN THE TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) | P2RY13, REN, PDGFRB | DRD1 4267/4885ABCB11 962/4885CYP2C19 643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.